By Chris Wack
Autonomix Medical shares were up 39% to $14.20 after the company said it saw positive results from a clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves to mitigate pain in patients with pancreatic cancer.
The medical device company said the first 15 patients in its ongoing proof-of-concept human clinical trial saw significant reduction in pain and improvement in regards to their pancreatic cancer pain.
Autonomix said it remains on track to complete enrollment by calendar year end.
Through seven days, the post-procedure showed a decrease in opioid demand, with no responding patient needing a dose increase. No responding patient needed opioids after their 24-hour post-procedure follow-up visit.
A total of twenty patients will be enrolled in the trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 31, 2024 09:54 ET (13:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。